American Headache Society Statement on CGRP Inhibitors is Driving Significant Change: Neurologist Peter McAllister, MD
"This AHS statement has exceeded our wildest dreams..." McAllister said of the impact of the society recommendation that CGRP inhibitors be considered among first-line treatment for migraine.
"The CGRP-targeting migraine therapies are a first-line option for migraine prevention. Initiation of these therapies should not require trial and failure of non-specific migraine preventive medication approaches."
This position statement from the American Headache Society (AHS) is the first of its kind from the organization calling for the calcitonin gene-related peptide (CGRP)-targeting therapies to be selected over traditional nonspecific agents used as first line preventive migraine treatment without requiring the time and frustration of the “trial and failure” protocol currently considered standard of care.
In an interview with Patient Care© migraine expert Peter McAllister, MD, noted, "There are very few other disease states that I treat where I have to use a 30- or 40- or 50-year-old medication that has limited efficacy and potentially lots of adverse events before I can get to something that was actually studied for the disease that's safe and well tolerated." His comments continue in the short video above.
Peter McAllister, MD, is associate professor of neurology at the Yale University School of Medicine, in New Haven, CT and co-founder and medical director of the New England Institute for Neurology and Headache, chief medical officer of New England Institute for Clinical Research and Ki Clinical Research, president and chief executive officer of Ki Management Services, in Stamford CT.
